Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke (ENOS)

Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke - Pilot, Single-center, Randomized, Patient-assessor Blinded, Sham-controlled Study

This study aims to investigate whether Remote Ischemic Conditioning (RIC) improves rheo-erythrocrine dysfunction in acute ischemic stroke

Study Overview

• Status: Completed
• Conditions: Cerebrovascular Disorders; Central Nervous System Diseases; Ischemic Stroke; Stroke, Acute
• Intervention / Treatment: Device: Remote Ischemic Conditioning; Device: Sham Remote Ischemic Conditioning

Detailed Description

Stroke is a leading cause of death and disability worldwide. Of all strokes, 85% are ischemic strokes caused by a thrombus or an embolus. The additional 15% are caused by hemorrhage. Currently the only approved treatments for ischemic strokes are thrombolysis given within 4.5 hours and thrombectomy performed within 6 hours of symptom onset - in some cases up to 24 hours. The majority of stroke patients are not however eligible for acute reperfusion therapy, mainly due to time constrains and late presentation. Novel neuroprotective strategies available for all stroke patients are thus urgently needed.

Remote Ischemic Conditioning (RIC) is a simple intervention in which transient ischemia is induced in an extremity by repetitive inflation-deflation of a blood pressure cuff. It remains uncertain exactly how the protective effect of RIC is transmitted and communicated between the extremity and the brain. Both humoral, immunological and neuronal pathways seem to be involved. Treatment with RIC and has proven to be a safe, feasible and low-cost treatment in clinical settings.

Biomarkers of the RIC treatment is a new area of stroke research and are important to establish in order to assess and predict responders of the conditioning treatment. Rheo-erythrocrine dysfunction of the Red Blood Cell (RBC) is a novel biomarker in both ischemic strokes in general and on the effect of RIC. Red Blood Cells with a diameter of 6-8 μm must be highly deformable in order to deliver oxygen to brain tissue by travelling through micro vessels with a diameter of just 2-3 μm. RBC's can carry nitric oxide as NO2-/s-nitrosylated proteins. These proteins improve RBC deformability and induce hypoxic vasodilation thereby improving passage through the microvasculature. RBC's also express Erythrocyte Nitric Oxide Synthase 3, which regulate the rheo-erythrocrine function. Erythrocyte Nitric Oxide Synthase 3 is activated by shear stress and provide an extra source of NO for hypoxic vasodilation. Preliminary data have shown that experimental stroke on mice seems to cause a rheo-erythrocrine dysfunction of the RBC's leading to a loss of deformability. The RBC's become rigid, which can lead to occlusion of micro vessels in the brain and further ischemic damage. Loss of deformability can be measured as a reduced Elongation Index (EI) by ektacytometry and may be attenuated by RIC.

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Denmark
  • Aarhus, Denmark, 8200
    • Aarhus University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

STROKE PATIENTS

Inclusion Criteria:

• Onset to randomization < 48 hours
• Independent in daily living (mRS 0-2)
• Legal competent
• Ambulatory
• Documented ischemic stroke on baseline MRI

Exclusion Criteria:

• Prior stroke, dementia or other known neurological condition Pregnancy
• Contraindications to MRI
• Investigators discretion
• Known upper extremity peripheral arterial stenosis Diabetes

CONTROLS

Inclusion Criteria:

• Independent in daily living (mRS 0-2) Ambulatory
• Legal competent
• Non vascular diagnosis (e.g. epilepsy, migraine etc.)

Exclusion Criteria

• Prior stroke, dementia or other known neurological condition
• Pregnancy
• Contraindications to MRI
• Investigators discretion
• Known upper extremity peripheral arterial stenosis Diabetes

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Remote Ischemic Conditioning; Remote Ischemic Conditioning (RIC) is applied during the in-hospital phase using an automated RIC device. Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be 200 mmHg; if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.; Initial Remote Ischemic Conditioning: < 2 hours from inclusion; Remote Ischemic Postconditioning: twice daily for 7 days Usual care with or without acute reperfusion therapy	Device: Remote Ischemic Conditioning; RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion
Sham Comparator: Sham - Remote Ischemic Conditioning; Sham Remote Ischemic Conditioning (Sham-RIC) is applied during the in-hospital phase using an automated Sham-RIC device. Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes of cuff deflation. The cuff pressure will be always be 20 mmHg.; Initial Sham Remote Ischemic Conditioning: < 2 hours from inclusion; Sham Remote ischemic Postconditioning: twice daily for 7 days Usual care with or without acute reperfusion therapy.	Device: Sham Remote Ischemic Conditioning; Sham Comparator (Sham-RIC)
No Intervention: Controls; The control group will not receive treatment with Remote Ischemic Conditioning.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
RBC deformability will serve as a biomarker of the conditioning response and predictor of the clinical outcome in stroke patients.	RBC deformability is measured as Deformability or Elongation Index (DI or EI, Rheoscan AnD-300, RheoMeditech, South Chorea). A higher EI at the optimum viscosity (300 Osmolality) indicates highly deformable RBCs indicative of better microcirculation, while a lower EI indicates rigid RBC's. Briefly, 6 µL of heparinized or EDTA treated fresh blood is mixed with 600-µL of polyvinylpyrrolidone (PVP) solution (300 Osm) and transferred to a disposable kit. The kit is placed inside the laser-assisted ectacytometer for automated read out, data and image collection as per the vendor's instructions.	1 week
RBC deformability will serve as a biomarker of the conditioning response and predictor of the clinical outcome in stroke patients	For measurement of shear stress, 0,5 mL of heparinized or EDTA treated fresh blood is mixed with 600-µL of polyvinylpyrrolidone (PVP) solution (300 Osm) and transferred to a disposable kit. The kit is placed inside the laser-assisted ectacytometer for automated read out, data and image collection as per the vendor's instructions.	1 week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nitric oxide quantification using DAF-FM-Diacetate flowcytometry as a biomarker of the conditioning response	Analytical flowcytometry with DAF-FM-Diacetate (4-Amino-5-Methylamino-2',7'-Difluorofluorescein Diacetate) on wholeblood samples	1 week
Nitric oxide quantification using DAF-FM-Diacetate flowcytometry as a predictor of the short term clinical outcome in stroke patients	Analytical flowcytometry with DAF-FM-Diacetate (4-Amino-5-Methylamino-2',7'-Difluorofluorescein Diacetate) on wholeblood samples	1 week
RBC deformability presentation across stroke subtypes	Ektacytometry (see primary outcome)	1 week
RBC deformability in relation to infarct size/stroke severity	Ektacytometry (see primary outcome)	1 week
RBC erythrocrine dysfunction (NOS3) presentation across stroke subtypes	Comparison of RBC Nitric Oxide Synthestase 3 activation (flowcytometry) across stroke subtypes.	9 months
RBC erythrocrine dysfunction (nitric oxide) presentation across stroke subtypes	Comparison of nitric oxide estimation (chemiluminescence) across stroke subtypes	9 months
RBC erythrocrine dysfunction (NOS3) in relation to infarct size/stroke severity	Level of RBC Nitric Oxide Synthestase 3 activation (flowcytometry)	9 months
RBC erythrocrine dysfunction (nitric) in relation to infarct size/stroke severity	Level of nitric oxide estimation (chemiluminescence)	9 months
Difference in 7 days cognitive impairment between treatment groups	Difference between baseline Montreal Cognitive Assessment (MoCA) score and day 7 MoCA score. MoCA is a 1-page (healthcare administered), 0-30-point test (30 is the best score), administrable in ≈10 minutes. The test evaluates different domains: visuospatial abilities, executive functions, short-term memory recall, attention, concentration, working memory, language, and orientation to time and space.	1 week
RBC erythrocrine dysfunction and deformability as a marker for difference in 7 days cognitive impairment (MoCA scale)	Cognitive impairment is measured using the Montreal Cognitive Assessment scale (MoCA), which is a 1-page (healthcare administered), 0-30-point test (30 is the best score), administrable in ≈10 minutes. The test evaluates different domains: visuospatial abilities, executive functions, short-term memory recall, attention, concentration, working memory, language, and orientation to time and space	9 months
Circulating microRNA profile of RIC-induced neuroprotection	MicroRNAs will be identified with Illumina next-generation sequencing using the TruSeq Small RNA Sample Preparation kit. The output will be miRNA expression levels for each sample, which will form the basis for a miRNA differential analysis where miRNAs with statistically significant expression changes will be found	9 months
Extracellular vesicle profile of RIC-induced neuroprotection	Extracellular vesicles (EVs, also known as exosomes) will be isolated from plasma samples before characterization of surface markers and content. Protein characterization will be done using ELISA and Western blots in addition to array techniques. To broaden the feasibility of finding stroke type specific EV surface markers, we will utilize recombinant antibody library techniques to find novel disease binders with the potential of diagnosing stroke types in blood samples. Nucleic acid (DNA and RNA including miRNA) content of EVs will be analyzed using next generation sequencing (NGS) and qRT-PCR	9 months
Circulating microRNA as a marker for difference in 7 days cognitive impairment (MoCA score)	Cognitive impairment is measured using the Montreal Cognitive Assessment scale (MoCA), which is a 1-page (healthcare administered), 0-30-point test (30 is the best score), administrable in ≈10 minutes. The test evaluates different domains: visuospatial abilities, executive functions, short-term memory recall, attention, concentration, working memory, language, and orientation to time and space	9 months
Extracellular vesicle profile as a marker for RBC erythrocrine dysfunction and deformability	Extracellular vesicles (EVs, also known as exosomes) will be isolated from plasma samples before characterization of surface markers and content. To broaden the feasibility of finding stroke type specific EV surface markers, we will utilize recombinant antibody library techniques to find novel disease binders with the potential of diagnosing stroke types in blood samples.	9 months

Collaborators and Investigators

• Sponsor: Grethe Andersen
• Investigators: Principal Investigator: Grethe Andersen, MD, DMSc, Aarhus University Hospital, Department of Neurology

Study record dates

Study Major Dates

• Study Start (Actual): July 29, 2020
• Primary Completion (Actual): July 31, 2021
• Study Completion (Actual): July 31, 2021

Study Registration Dates

• First Submitted: February 3, 2020
• First Submitted That Met QC Criteria: February 11, 2020
• First Posted (Actual): February 12, 2020

Study Record Updates

• Last Update Posted (Actual): February 17, 2022
• Last Update Submitted That Met QC Criteria: February 16, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: Neuroprotection; Remote Ischemic Conditioning
• Additional Relevant MeSH Terms: Pathologic Processes; Necrosis; Cardiovascular Diseases; Vascular Diseases; Brain Diseases; Brain Ischemia; Infarction; Brain Infarction; Stroke; Ischemic Stroke; Ischemia; Nervous System Diseases; Cerebral Infarction; Cerebrovascular Disorders; Central Nervous System Diseases
• Other Study ID Numbers: ENOS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No